<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991532</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2021-130</org_study_id>
    <nct_id>NCT04991532</nct_id>
  </id_info>
  <brief_title>Dasatinib Down-regulates the Expression of PD-1 and Enhances Killing pH + Leukemia Stem Cells</brief_title>
  <official_title>Research on the Mechanism of Dasatinib Down-regulates the Expression of PD-1 in CMV-activated NKG2C+NK Cells and Enhances Killing pH + Leukemia Stem Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research on the mechanism of dasatinib down-regulates the expression of PD-1 in CMV-activated&#xD;
      NKG2C+NK cells and enhances killing pH + leukemia stem cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some patients with CML can withdraw from TKIs after treatment, and the mechanism might be&#xD;
      related to the effect of memory NK cells on anti-Ph+ leukemic stem cells (LSCs). Dasatinib&#xD;
      affects immune through several pathways including the expression of PD1 in immune cells. Our&#xD;
      previous work showed increased NKG2C+ NK cells were found in cases with CMV-DNA+ who suffered&#xD;
      Ph+ leukemia and received Dasatinib, and these memory NK cells have anti-LSCs activity. We&#xD;
      hypothesize that: CMV infection activates NKG2C+ memory NK cells proliferation; Dasatinib&#xD;
      down-regulates the expression of PD1 in PD1+NKG2C+ NK cell subsets and then enhances&#xD;
      anti-LSCs activity of these cells. In this study, the effect of Dasatinib on CMV-activated&#xD;
      NKG2C+ cell subsets and its mechanism will be studies. Besides, the different NKG2C+ cell&#xD;
      subsets on LSCs will be compared. This study might be helpful to clarify the mechanism of TKI&#xD;
      withdrawal and to offer foundation for CMV and Ph+ ALL treatment strategies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NK cells and T cell activation subsets in CML-CP patients treated with TKI for 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>NK cells and T cell activation subsets in CML-CP patients treated with TKI for 2 years</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Dasatinib group</arm_group_label>
    <description>the CML patient treated with dasatinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib group</arm_group_label>
    <description>the CML patient treated with imatinib</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        CML-CP patients treated with TKIs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years old, gender is not limited&#xD;
&#xD;
          2. CML-CP patients treated with TKIs&#xD;
&#xD;
          3. No pregnancy was planned during the treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1.The researcher judged that it was not suitable to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Xu</last_name>
    <phone>+86-20-61641615</phone>
    <email>522111156@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weixiang Lu</last_name>
    <phone>+86-20-61641615</phone>
    <email>522111156@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Xu</last_name>
      <phone>+86-20-61641615</phone>
      <email>522111156@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>weixiang lu</last_name>
      <phone>+86-20-61641615</phone>
      <email>522111156@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Dan Xu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

